[49] In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo
Salvi served as co-lead counsel in negotiating global settlements totaling $456 million for nearly 900 plaintiffs
Incorrect solvent selection, excessive agitation, and improper storage after mixing are among the most common issues that compromise peptide integrity before an experiment even begins
Natural Science Fund Surface Project at Chongqing University of Science and Technology (CSTB2023NSCQ-MSX1060) and Chongqing Traditional Chinese Medicine Innovation Team Construction Project